Head-To-Head Survey: Tarsus Pharmaceuticals (NASDAQ:TARS) and CG Oncology (NASDAQ:CGON)

CG Oncology (NASDAQ:CGON) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for CG Oncology and Tarsus Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0	0	8	1	3.11
Tarsus Pharmaceuticals	0	1	4	1	3.00

CG Oncology currently has a consensus price target of $63.88, indicating a potential upside of 112.63%. Tarsus Pharmaceuticals has a consensus price target of $54.20, indicating a potential downside of 1.45%. Given CG Oncology’s stronger consensus rating and higher possible upside, research analysts plainly believe CG Oncology is more favorable than Tarsus Pharmaceuticals.

Institutional and Insider Ownership

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares CG Oncology and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	-10,642.98%	-18.97%	-15.36%
Tarsus Pharmaceuticals	-103.64%	-55.86%	-39.28%

Earnings & Valuation

This table compares CG Oncology and Tarsus Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$684,000.00	3,339.45	-$48.61 million	N/A	N/A
Tarsus Pharmaceuticals	$129.62 million	16.22	-$135.89 million	($3.81)	-14.44

CG Oncology has higher earnings, but lower revenue than Tarsus Pharmaceuticals.

Summary

CG Oncology beats Tarsus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.